The femoropopliteal (FP) segment is increasingly treated via an endovascular-first approach for both lifestyle limiting claudication and critical limb ischemia. Nitinol stents have been shown to be superior to percutaneous transluminal angioplasty (PTA) and have become one of the primary modalities for the treatment of FP obstructive atherosclerotic disease due to improved structural integrity and conformability of newer devices [1] [2] [3] . Current nitinol stents have low rates of stent fracture and excellent clinical patency out to three years 2, 4 . Despite these advances, FP in-stent restenosis (FP-ISR) remains an important clinical problem, occurring in up to 19-37% of cases following stenting of moderate length (up to 150mm) lesions and more frequently following treatment of longer lesions 1,2,5 .
Tosaka and colleagues 6 have described the angiographic patterns of FP-ISR. Class I FP-ISR consists of focal (<50 mm) ISR within the stent body, stent edge, or a combination of the two. Class II FP-ISR consists of diffuse lesions (>50 mm) within the stent body and/or stent edge.
Class III FP-ISR lesions consist of total occlusion within the stent. They described the outcomes of PTA for the treatment of FP-ISR and found that instent occlusion (Class III FP-ISR) was a significant predictor of recurrent restenosis (84.8%) and re-occlusion (64.6%) at two years. Twoyear outcomes for patients with focal (Class I) and diffuse (Class II) ISR were similar, with recurrent restenosis in 49.9% and 53.3%, and stent occlusion in 15.9% and 18.9%, respectively.
These results highlighted the lack of efficacy of PTA for FP-ISR, particularly for instent occlusion. In a follow-up to that study, we evaluated a multi-modality approach to the treatment of FP-ISR 7 . Seventy-five patients underwent endovascular treatment of FP-ISR using a variety of adjunctive devices, including laser atherectomy, excisional atherectomy, and repeat stenting.
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The authors are to be congratulated for completing this important and carefully done study which highlights the fact that locally delivered paclitaxel during balloon angioplasty can result in effective inhibition of neointimal proliferation and clinical benefit at 12 months, when used for the treatment of FP-ISR. The strengths of this study consist of its randomized, multicenter design, adjudicated follow-up duplex and angiographic assessment, and careful clinical and hemodynamic evaluation before and after intervention. Important limitations of the study include its relatively small size and short duration of follow-up. The primary endpoint assessment was only at 6 months, and there was significant patient drop out at 12months, limiting the conclusiveness of the 12-month duplex findings. In this study (as was the case in most DCB trials), the operator was not blinded to the treatment given, thus introducing potential bias. This is possibly reflected in the different rates of bailout stenting between the PTA and DCB groups (7.0% vs. 1.6%). The lesion lengths in this trial were relatively short, and it is unclear what the benefit of DCB would be for longer or more diffuse FP-ISR. It is also worthy of mention, that despite the apparent benefits of DCB with regards to reduction in recurrent restenosis and need for TLR, there was no improvement in relative or absolute claudication distance for patients treated with DCB compared to those treated with PTA in this trial. Preliminary experience with laser atherectomy followed by DCB has been encouraging 20 .
We look forward to further comparative studies of DCB and other modalities for the treatment of FP-ISR. In the meantime, it is FAIR to assume that DCBs will play an increasingly important role in the treatment of this challenging clinical problem. n future randomized trials. Combination approaches utilizing dr a ug-coated balloo ons ns ns i i in n n r conjunction with atherectomy may also hold promise, particularly for complex ISR lesions.
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